By Wendy Van Sickle
Columbus, Ohio, March 9 – JPMorgan Chase Financial Co. LLC priced $1.39 million of 0% review notes Feb. 27, 2026 linked to the lesser performing of the ARK Innovation ETF and the ARK Genomic Revolution ETF, according to a 424B2 filing with the Securities and Exchange Commission.
The notes will be called at par plus an annual call premium of 17.5% if each asset closes at or above its initial level on any annual review date.
If the notes are not called, the payout at maturity will be par unless either asset falls by more than 50%, in which case investors will be fully exposed to any losses of the worse performing index or fund.
The notes are guaranteed by JPMorgan Chase & Co.
J.P. Morgan Securities LLC is the agent.
| Issuer: | JPMorgan Chase Financial Co. LLC
|
| Guarantor: | JPMorgan Chase & Co.
|
| Issue: | Review notes
|
| Underlying assets: | ARK Genomic Revolution ETF, ARK Innovation ETF
|
| Amount: | $1,392,000
|
| Maturity: | Feb. 27, 2026
|
| Coupon: | 0%
|
| Price: | Par
|
| Call: | At par plus 17.5% per year if each asset closes at or above its initial level on any annual review date
|
| Payout at maturity: | If each asset finishes at or above 50% trigger level, par; otherwise, 1% loss for each 1% decline of worse performing index or fund
|
| Initial levels: | $98.84 for Genomic, $138.32 for Innovation
|
| Trigger levels: | $49.42 for Genomic, $69.16 for Innovation; 50% of initial levels
|
| Pricing date: | Feb. 24
|
| Settlement date: | March 1
|
| Agent: | J.P. Morgan Securities LLC
|
| Fees: | 4.125%
|
| Cusip: | 48132RE30
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
